ONCONASE Enhances Effect Of Radiation In Non-Small Cell Lung Cancer
ONCONASE significantly enhances the effect of the radiation response in human non-small cell lung cancer (NSCLC) in vitro and in vivo.
The ongoing research conducted at the University of Pennsylvania shows that in cell culture (in vitro) studies using A549 human NSCLC cells, ONCONASE increased the radiation response by inducing inhibition of O2 consumption in tumor cells. The occurrence of apoptosis (cell death) was increased by ONCONASE and was dependent on ONCONASE dosage and length of exposure. Additionally, in animal (in vivo) studies, ONCONASE significantly increased the radiation-induced tumor growth delay of A549 human NSCLC tumors. Other findings from the research indicated that ONCONASE could also be a good candidate for the treatment of gefitinib resistant NSCLC.
"This investigation suggests important potential clinical uses of ONCONASE for the treatment of NSCLC cancer patients," said Intae Lee, Ph.D., of the University of Pennsylvania.
Kuslima Shogen, Alfacell's chairman and chief executive officer, added: "This research further supports our efforts to expand the use of ONCONASE into therapeutic areas that may benefit all patients suffering from cancer."
ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.